Cleared Traditional

K890001 - DOUBLE ANTIBODY SERUM BENZODIAZEPINES

K890001 is the FDA 510(k) clearance for DOUBLE ANTIBODY SERUM BENZODIAZEPINES by Diagnostic Products Corp.. It is a Class 2 Toxicology device (product code JXM) cleared through the Traditional 510(k) pathway after a 21-day FDA review.

K890001 · Diagnostic Products Corp. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1989
Decision
21d
Days
Class 2
Risk

K890001 is an FDA 510(k) clearance for the DOUBLE ANTIBODY SERUM BENZODIAZEPINES. Classified as Enzyme Immunoassay, Benzodiazepine (product code JXM), Class II - Special Controls.

Submitted by Diagnostic Products Corp. (Los Angeles, US). The FDA issued a Cleared decision on January 24, 1989 after a review of 21 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3170 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Diagnostic Products Corp. devices

Submission Details

510(k) Number K890001 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 03, 1989
Decision Date January 24, 1989
Days to Decision 21 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
66d faster than avg
Panel avg: 87d · This submission: 21d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JXM Enzyme Immunoassay, Benzodiazepine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3170
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - JXM Enzyme Immunoassay, Benzodiazepine

All 65
Devices cleared under the same product code (JXM) and FDA review panel - the closest regulatory comparables to K890001.
BENZODIAZEPINES/TRICYCLIC ANTIDEPRESSANTS BY HPLC
K896744 · Bio-Rad · Feb 1990
ADX TM BENZODIAZEPINES
K890691 · Abbott Laboratories · Aug 1989
ABUSCREEN FP BENZODIAZEPHINE REAGENT
K891697 · Roche Diagnostic Systems, Inc. · Mar 1989
TDX BENZODIAZEPINES SERUM
K883730 · Abbott Laboratories · Nov 1988
DOUBLE ANTIBODY BENZODIAZPINES #KBZD1, KBZD5
K883459 · Diagnostic Products Corp. · Sep 1988
REVISIED LABELING FOR ADX BENZODIAZEPINES
K880014 · Abbott Laboratories · Feb 1988